摘要:
The invention provides polypeptides comprising inhibitor of apoptosis protein (IAP) family members, such as BmIAP initially derived from Bombyx mori BmN cells, and nucleic acids encoding them, and methods for making and using these compositions, including their use for inhibiting apoptosis.
摘要:
The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by Formula 1 wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R1-R4 is hydrogen, R2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R4 is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R1 and R3 is each independently C1-C20 substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.
摘要翻译:本发明提供在治疗高血压的治疗应用中抑制环氧化物水解酶的化合物。 用于实施本发明的一类优选的化合物具有式1所示的结构,其中Z是氧或硫,W是碳磷或硫,X和Y各自独立地是氮,氧或硫,并且X还可以是碳, R 1至R 4中的至少一个为氢,当X为氮时,R 2为氢,但当X为硫或不存在时不存在 当Y为氮时,氧,R 4为氢,但当Y为硫或氧时不存在,R 1和R 3各自独立地为 C 1 -C 20取代或未取代的烷基,环烷基,芳基,酰基或杂环。
摘要:
The invention relates to methods, compositions, and uses of those compositions for making medicaments, for potentiating the beneficial effects of inhibitors of COX-1, COX-2, and 5-LOX, and reducing adverse effects, by also administering inhibitors of soluble epoxide hydrolase (“sEH”), with or without also administering one or more cis-epoxyeicosantrienoic acids. The invention further relates to the use of inhibitors of sEH as analgesics and to methods and compositions of epoxides of eicosapentaenoic acid and docosahexaenoic acid, optionally with an inhibitor of sEH, to reduce pain or inflammation or both.
摘要:
The invention provides uses and methods for reducing brain damage from stroke. The uses comprise the use of an inhibitor of soluble epoxide hydrolase (sEH) for the manufacture of a medicament to reduce brain damage from stroke, as well as the use of cis-epoxyeicosatrienoic acid (EET) for that purpose. The methods comprise the administration of sEH inhibitors to persons who have had a stroke, or who are at risk of having a stroke. Optionally, the methods also include the administration of EETs.
摘要:
Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.
摘要:
The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by Formula I wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R1—R4 is hydrogen, R2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R4 is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R1 and R3 is each independently C1-C20 substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.
摘要翻译:本发明提供在治疗高血压的治疗应用中抑制环氧化物水解酶的化合物。 用于实施本发明的优选类化合物具有式I所示的结构,其中Z是氧或硫,W是碳磷或硫,X和Y各自独立地是氮,氧或硫,并且X还可以是碳, R 1至R 4中的至少一个为氢,当X为氮时,R 2为氢,但当X为硫或不存在时不存在 当Y为氮时,氧,R 4为氢,但当Y为硫或氧时不存在,R 1和R 3各自独立地为 C 1 -C 20取代或未取代的烷基,环烷基,芳基,酰基或杂环。
摘要:
The invention provides methods of using dihydroxy unsaturated fatty acids as markers for identifying patients with a disorder associated with abnormal regulation of the cytochrome P450 metabolism or oxidation of unsaturated fatty acids. For example, linoleic acid diols, including leukotoxindiol, can be used as a diagnostic tool for identifying patients with pre-eclampsia, eclampsia, and pregnancy-induced hypertension.
摘要:
Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.
摘要:
It has now been discovered that inhibitors of soluble epoxide hydrolase (“sEH”) are useful in reducing the severity of or inhibiting the progression of obstructive pulmonary diseases, restrictive airway diseases, and asthma. Administering a cis-epoxyeicosantrienoic acid (“EET”) in addition to the inhibitor is at least additive, and may be synergistic, in reducing or inhibiting these conditions and diseases, as measured by reduced numbers of neutrophils present in the lung. The inhibitor of sEH may be a nucleic acid, such as a small interfering RNA.